Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. BLCO
BLCO logo

BLCO News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

BLCO News

Bausch + Lomb Achieves Key Milestone in Glaucoma Treatment with ELIOS System

1d agoseekingalpha

Bausch + Lomb Reports Positive ELIOS System Clinical Trial Results

1d agoNewsfilter

Caspian Capital Increases Stake in Bausch + Lomb Corporation

Mar 12 2026Fool

Caspian Capital Increases Stake in Bausch + Lomb Corporation

Mar 12 2026NASDAQ.COM

Bausch + Lomb Launches First R&D Webinar Series

Mar 09 2026Newsfilter

Bausch + Lomb Reports Record Q4 2025 Earnings Performance

Feb 18 2026seekingalpha

Bausch + Lomb Q4 Earnings Beat Expectations with Revenue Growth

Feb 18 2026seekingalpha

Bausch + Lomb Launches Fifth Annual Glaucoma Fundraising Challenge with $20,000 Match

Jan 05 2026Newsfilter

BLCO Events

03/23 07:10
Bausch + Lomb ELIOS System Clinical Trial Results Significant
Bausch + Lomb announced 24-month results from the pivotal U.S. clinical trial of the ELIOS System. Developed for the treatment of elevated intraocular pressure in patients with open angle glaucoma, ELIOS is an implant-free procedure that uses next generation excimer laser technology. The ELIOS procedure is currently CE marked in Europe and is under development and has not been reviewed by the FDA for safety and efficacy in the United States . "These strong U.S. study results reinforce everything we've learned about ELIOS during the years it has been available in Europe," said Yehia Hashad, MD, executive vice president, R&D and CMO. "Achieving meaningful reductions in intraocular pressure and freedom from medication for a majority of patients speaks to the promise of this technology. We look forward to sharing the full dataset with the broader ophthalmic community." In the prospective, multicenter study, investigators at 20 sites across the U.S. enrolled 318 patients taking glaucoma medications. Patients were previously diagnosed with mild to moderate primary open-angle glaucoma as well as cataracts. Two co-primary effectiveness endpoints were evaluated: the percentage of patients achieving at least a 20% reduction in IOP, and mean IOP reduction. The ELIOS system met the study's co-primary effectiveness endpoints, demonstrating both statistically significant and clinically meaningful IOP reduction. Key results included: Unmedicated diurnal IOP was reduced by 20% or greater in 76% of patients; Patients experienced an average of 7.4 mmHg decrease in unmedicated DIOP; 82% of patients were medication-free at 23 months; No intraoperative complications seen during the ELIOS procedure; Similar postoperative adverse event rate as cataract surgery alone.
02/25 10:10
IBM Secures $112M Contract with Department of War
Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly.TARIFF REFUNDS:Bausch + Lomb, L'Oreal, and Dyson are suing for refunds of tariffs paid under President Donald Trump's emergency trade measures, days after the U.S. Supreme Court ruled the duties unlawful, Arriana McLymore of Reuters. More than 1,400 importers including Costcoand Goodyearhave already sued, court documents show, and trade lawyers expect a wave of additional lawsuits as companies try to recover billions of dollars in duties. FedExalso filed a complaint this week.CITIZENSHIP INFO:President Trump's administration is weighing a possible executive order or other action that would require banks to collect citizenship information from customers in "a new front in the administration's crackdown on immigrants living in the U.S. illegally," according to's Dylan Tokar and Natalie Andrews, citing people familiar with the matter. Ultimately, banks may be tasked with asking for an unprecedented new category of documents, such as a passport, from both new and pre-existing customers who want to maintain a U.S. bank account, the report stated. Publicly traded large cap banks include Bank of America, Citi, Goldman Sachs, JPMorgan, Morgan Stanley, U.S. Bancorpand Wells Fargo.DOW CONTRACT:IBMhas secured a contract with a ceiling value of $112M for up to five years from the Department of War's, or DoW, Defense Commissary Agency, or DeCA, to modernize pricing displays across commissaries worldwide, aimed to enhance operational efficiency and improve the shopping experience for military personnel and their families. This investment represents a step in advancing digital retail infrastructure for the DoW. Under the agreement, IBM will upgrade the existing Electronic Shelf Label system at 177 U.S. commissaries and install new systems at 58 overseas locations in 12 countries. Additional expected benefits of the new ESL system include: Accurate pricing and availability: Enables real-time price updates and enhanced product availability for military personnel and their families; Operational efficiency: Streamlines processes to reduce manual labor, aligning with the DoW's digital transformation goals. As part of the contract, IBM will provide hardware maintenance, software licenses, security, vulnerability mitigation, training, and ongoing support for existing ESL infrastructure - including proprietary Pricer ESL software and hardware, third-party components such as Windows operating systems, and the web-based ordering platform integrated within DeCA's environment. Overseas installations are scheduled to begin in early 2026.
02/24 16:00
Bausch + Lomb, L'Oreal, and Dyson Sue for Tariff Refunds
Bausch + Lomb, L'Oreal, and Dyson are suing for refunds of tariffs paid under President Donald Trump's emergency trade measures, days after the U.S. Supreme Court ruled the duties unlawful, Arriana McLymore of Reuters reports. More than 1,400 importers including Costco (COST) and Goodyear (GT) have already sued, court documents show, and trade lawyers expect a wave of additional lawsuits as companies try to recover billions of dollars in duties. FedEx (FDX) also filed a complaint this week.

BLCO Monitor News

No data

No data

BLCO Earnings Analysis

Bausch + Lomb Earnings: Vision Care & Pharma Growth- Intellectia AI™
1 years ago

People Also Watch